Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited (CLVLF) Stock Overview
Explore Clinuvel Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
401M
P/E Ratio
17.27
EPS (TTM)
$0.50
ROE
0.19%
CLVLF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Clinuvel Pharmaceuticals Limited (CLVLF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 94.04, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $6.75.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.27 and a market capitalization of 401M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.